AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE: ABBV) company.
As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa.
"BeiGene's work is original, and we will vigorously defend against all allegations of patent infringement," the company said.
Imbruvica (ibrutinib) is a once-daily oral medication jointly developed and commercialized by Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ) and Pharmacyclics.
BeiGene said that most recently, the ALPINE study, a head-to-head comparison between Brukinsa and Imbruvica in R/R CLL/SLL, demonstrated Brukinsa's superior efficacy (PFS and ORR) and safety (atrial fibrillation) over Imbruvica.
The study also reported zero sudden cardiac death events for Brukinsa versus a 1.9% rate for Imbruvica.
Global sales of Brukinsa reached $211.4 million for Q1 2023, compared to $104.3 million a year ago.
Price Action: BGNE shares are down 0.37% at $207.36 on the last check Thursday.
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
This article AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
